TICKERNERD
Menu
LFWDLFWDHealthcare · Medical Devices

LFWD Stock Forecast: Lifeward Ltd. Price Predictions for 2026-2027

Last close, 20 Aug 2026
$7.33
+0.83% on the day

The 2 Wall Street analysts covering Lifeward Ltd. hold a median 12-month price target of $20 — +172.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$20.7M
Ticker Nerd rank
21 / 100
Median analyst target
$20
Analysts covering
2
Total return, dividends reinvested
1W
−7.2%
1M
−2.9%
YTD
+5.9%
1Y
−0.0%
From 52W high
−26.2%
From 52W low
+59.5%
$4.60
$9.94
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LFWD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lifeward Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
88
Accruals
64
Growth
50
Momentum
39
Volatility
30
Quality
29
Revisions
26
Value
22
Issuance
4

Size (88): Smaller than most of the companies we track.

Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LFWD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LFWD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00$25.00$30.00Oct 25Jan 26Apr 26Jul 26LFWDHigh $30Median $20Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $10Median $20High $30

The green dot is the last close — the median target sits +172.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Mar 2026HC Wainwright & Co.MaintainsBuy$4.50 → $10
18 Nov 2025HC Wainwright & Co.MaintainsBuy—
11 Mar 2025HC Wainwright & Co.ReiteratesBuy—
11 Mar 2025Lake StreetMaintainsBuy—
20 Feb 2025HC Wainwright & Co.ReiteratesBuy—
20 Feb 2025Lake StreetMaintainsBuy—
10 Feb 2025Laidlaw & Co.InitiatesBuy—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy—
16 Aug 2024HC Wainwright & Co.MaintainsBuy—
16 May 2024HC Wainwright & Co.MaintainsBuy—
15 Apr 2024HC Wainwright & Co.ReiteratesBuy—
28 Feb 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2023HC Wainwright & Co.ReiteratesBuy—
14 Aug 2023HC Wainwright & Co.ReiteratesBuy—
10 Aug 2023HC Wainwright & Co.ReiteratesBuy—
3 July 2023HC Wainwright & Co.ReiteratesBuy—
12 May 2023HC Wainwright & Co.ReiteratesBuy—
24 Feb 2023HC Wainwright & Co.ReiteratesBuy—
15 Nov 2022HC Wainwright & Co.MaintainsBuy—
10 Aug 2022HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LFWD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LFWD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Lifeward Ltd. (LFWD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 80% of US stocks

Price / sales
0.9×

Cheaper than 71% of US stocks

Price / book
3.2×

Cheaper than 33% of US stocks

EV / EBITDA
−0.8×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
15.7%

Higher than 64% of US stocks

Earnings growth (YoY)
−22.1%

Higher than 19% of US stocks

Gross margin
34.2%

Higher than 41% of US stocks

Operating margin
−62.7%

Higher than 16% of US stocks

Net margin
−141.3%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−225.6%

Higher than 6% of US stocks

Return on assets
−47.3%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LFWD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
LFWDLifeward Ltd.$20.7M
21
PLSMPulsenmore Ltd.$20.0M
30
NMTCNeuroOne Medical Technologies Corp.$18.5M
49
CTSOCytoSorbents Corp.$23.2M
47
TELATELA Bio, Inc.$28.8M
27
MODDModular Medical, Inc.$28.9M
11
ADGMAdagio Medical Holdings, Inc.$13.7M
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lifeward Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LFWD news & analysis

Lifeward (LFWD) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 14 Aug 2026positive

Lifeward (LFWD) reported a Q2 loss of $1.46 per share, narrower than the Zacks Consensus Estimate of a $1.49 loss and well below the $6.96 loss per share recorded a year earlier, though revenue missed estimates. The quarterly results compare favorably to both consensus and the prior-year period.

Why it matters — LFWD watchers would care because the narrower-than-expected loss signals improving financial performance even as the company fell short of revenue estimates.

Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth

GlobeNewsWire · 14 Aug 2026positive

Lifeward Ltd. reported strong second quarter 2026 financial results, citing revenue growth and improved operating performance as its capital-efficient distribution strategy gains traction.

Why it matters — The results signal that Lifeward's commercial execution and rehabilitation-platform expansion are strengthening its financial position and operational momentum.

Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026

GlobeNewsWire · 7 Aug 2026neutral

Lifeward Ltd. announced it will report its second quarter 2026 financial results on August 14, 2026, with a press release and SEC filing prior to 9:30 a.m. ET, and stated it will not hold a conference call.

Why it matters — This announcement provides the specific date and details for the upcoming quarterly financial disclosure, which LFWD watchers will look to for the company's performance update.

Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton

GlobeNewsWire · 5 Aug 2026positive

Lifeward launched a pilot program with Ottobock Care, a leading U.S. mobility technology patient care organization, to expand national access to its ReWalk Personal Exoskeleton. The program uses Ottobock's clinical expertise and patient care infrastructure to broaden ReWalk's reach.

Why it matters — The partnership advances Lifeward's strategy to broaden ReWalk access through a capital-efficient channel partner model intended to accelerate growth, expand patient access, and improve commercial scalability.

FAQ

Frequently asked questions about LFWD stock

What is the LFWD stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Lifeward Ltd. have a median 12-month price target of $20, with estimates ranging from $10 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LFWD stock a buy right now?

Of the 2 analysts covering Lifeward Ltd., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lifeward Ltd. 21 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LFWD?

As at 22 Aug 2026, Lifeward Ltd. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).

Will LFWD stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +172.9% from the last close, and Ticker Nerd's factor model ranks Lifeward Ltd. 21 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LFWD stock forecast for 2030?

No analyst covering Lifeward Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LFWD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $30 over the next 12 months.

How has LFWD stock performed over the past year?

Lifeward Ltd. returned -0.0% over the 12 months to 20 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lifeward Ltd. do?

Lifeward Ltd. is a medical technology company specializing in solutions for physical rehabilitation and mobility.

What is the latest news on LFWD?

The most recent item we track (Zacks Investment Research, 14 Aug 2026): "Lifeward (LFWD) Reports Q2 Loss, Misses Revenue Estimates". Lifeward (LFWD) reported a Q2 loss of $1.46 per share, narrower than the Zacks Consensus Estimate of a $1.49 loss and well below the $6.96 loss per share recorded a year earlier, though revenue missed estimates. The quarterly results compare favorably to both consensus and the prior-year period.

Company

About Lifeward Ltd.

Lifeward Ltd. is a medical technology company specializing in solutions for physical rehabilitation and mobility. The company designs, develops, and markets wearable robotic exoskeletons that provide powered hip and knee motion, enabling individuals with spinal cord injuries to stand, walk, turn, and navigate stairs in clinical, home, and community settings. Lifeward’s portfolio extends beyond exoskeletons to include technologies such as anti-gravity treadmills, functional electrical stimulation systems, and soft exo-suits, all aimed at improving gait training, strength, and functional independence during recovery and long-term care. These products are used by rehabilitation hospitals, outpatient clinics, and patients at home, integrating into multidisciplinary therapy programs. Headquartered in Hudson, Massachusetts, Lifeward operates within the broader medical device and rehabilitation equipment sectors, serving neurologic, orthopedic, and general rehabilitation markets. The company plays a specialized role in enabling advanced, technology-assisted rehabilitation and mobility support for individuals with significant walking impairments.

CEO Mr. William Mark Grant · 81 employees · Israel · https://golifeward.com